Lifestyle
- Regular physical activity
- Stress management techniques
- Smoking cessation
High-Sensitivity CRP · hs-CRP · C-Reaktives Protein hochsensitiv
hsCRP quantifies the concentration of C-reactive protein in the blood, reflecting low-grade systemic inflammation.
hsCRP levels >3 mg/L are considered high risk for cardiovascular events. Sex-specific differences may exist.
High-sensitivity C-reactive protein (hsCRP) is a refined version of the C-reactive protein test that measures low levels of CRP in the blood. CRP is an acute-phase protein produced by the liver in response to inflammation. The hsCRP test is sensitive enough to detect lower levels of inflammation that are associated with cardiovascular risk. Clinically, hsCRP is a significant marker for assessing the risk of cardiovascular diseases, particularly in individuals without known atherosclerotic cardiovascular disease (ASCVD). Researchers have found that elevated hsCRP levels are associated with an increased risk of major adverse cardiovascular events (MACE), cardiovascular death, and all-cause mortality. In the context of athletic performance and biohacking, hsCRP can be used to monitor systemic inflammation, which may affect recovery and overall health. Lower hsCRP levels are generally desirable for longevity and optimal health. However, researchers observed that hsCRP levels can be influenced by various factors, including acute infections, chronic inflammatory conditions, and lifestyle factors such as smoking and obesity. It is important to consider these confounders when interpreting hsCRP levels. The test does not require fasting, and while it is not highly time-of-day sensitive, consistent timing for repeated measures is recommended for comparability.
Klinische Bedeutung
Elevated hsCRP levels indicate increased inflammation and are associated with a higher risk of cardiovascular events. Lower levels suggest a lower risk of such events.
Progressively rising hsCRP values suggest worsening inflammation and increased cardiovascular risk. Retest in 4 weeks if outside optimal range.
Progressively falling values suggest reduced inflammation and potentially lower cardiovascular risk.
Re-test Interval
4 weeks if outside optimal range
Note:
Consult a healthcare provider before starting any new supplement regimen.
Draw at the same time of day for consistency.
Testing Frequency
Annually for cardiovascular risk assessment, more frequently if monitoring inflammation.
Correlated with
Current research suggests that sex-specific reference intervals for hsCRP are understudied, potentially leading to underdiagnosis in women. Researchers have not yet established optimal hsCRP targets for different populations, particularly in primary prevention settings. Additionally, clinical questions remain unanswered regarding the confounding effects of comorbidities and lifestyle factors on hsCRP levels and their implications for cardiovascular risk stratification.
1,269
Total Citations
24
Human/RCT
7.8
Avg. Influence
2025
Latest
This study discussed hsCRP's role in predicting vascular risk and its relationship with inflammation. Researchers observed that hsCRP levels are significant predictors of cardiovascular risk, especially in the context of statin therapy.
This review discussed the role of high-sensitivity C-reactive protein (hsCRP) in non-communicable diseases such as cardiovascular diseases and diabetes. Researchers highlighted hsCRP's potential as a reliable biomarker for predicting disease risk and the impact of lifestyle modifications on reducing hsCRP levels.
Ruscica Massimiliano, et al. · Atherosclerosis · 2019
This narrative review examined the relationship between high-sensitivity C-reactive protein (hs-CRP) and inflammation in atherosclerotic cardiovascular disease. Researchers noted that while PCSK9 inhibitors effectively lower LDL-C, they do not significantly affect hs-CRP levels, indicating the importance of hs-CRP in assessing residual cardiovascular risk.
Key findings
This review discussed the use of high-sensitivity C-reactive protein (hsCRP) in detecting cardiovascular diseases. Researchers highlighted its role as a biomarker of inflammation and its potential utility in diagnosing acute cardiovascular events, emphasizing the need for awareness of its association with cardiovascular risk.
Researchers found that hsCRP is a valuable biomarker for predicting cardiovascular risk and guiding treatment decisions. They highlighted the importance of measuring hsCRP alongside traditional risk factors and noted that lifestyle changes and medications can help lower hsCRP levels.
This population-based study evaluated hsCRP levels in nearly 450,000 individuals without known cardiovascular disease. Researchers found that higher hsCRP levels were associated with increased risks of major cardiovascular events and mortality, confirming its predictive value.
This study examined the role of traditional and emerging risk factors for coronary heart disease, including high-sensitivity C-reactive protein (hsCRP). Researchers found that new biological and genetic risk factors are reshaping the understanding of heart disease and improving risk assessment tools.
This study aimed to identify genetic factors associated with hsCRP levels in people living with HIV. Researchers found several genetic loci linked to elevated hsCRP, D-dimer, and interleukin-6 levels. The findings suggest that genetics may contribute to chronic inflammation in this population, highlighting potential targets for intervention.
This comprehensive review focused on salivary high-sensitivity C-reactive protein (hsCRP) as a non-invasive biomarker for chronic diseases. Researchers discussed its potential advantages over blood-based assays and emphasized the need for further validation and integration into clinical practice.
Researchers found significant correlations between elevated hs-CRP levels and various lipid and micronutrient markers in a cohort of individuals. The study highlighted that abnormal lipid levels and certain micronutrient deficiencies could contribute to increased hs-CRP, indicating a complex interplay between inflammation and metabolic health.
6
Total Trials
367
Total Enrolled
Universitat Internacional de Catalunya
28
2023
High-sensitivity C-reactive protein (hs-CRP) values in serum
University College Dublin
91
2023
Change in hsCRP level
Chr Hansen
42
2022
hs-CRP
University of Bath
32
2022
Change in hsCRP
Bota Bio Co., Ltd.
82
2016
hs-CRP (high-sensitivity C-reactive protein)
IKFE Institute for Clinical Research and Development
92
2005
Short-term effect of Pioglitazone on Markers of vascular risk (MMP-9, hsCRP, monocyte activation)
Research publications about hsCRP over time
10totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer